Article
Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.
The journal of medical investigation : JMI - 1 Jan 2017
Takeuchi Shinji, Yoshimura Kenichi, Fujiwara Tadami, Ando Masahiko, Shimizu Shinobu, Nagase Katsuhiko, Hasegawa Yoshinori, Takahashi Toshiaki, Katakami Nobuyuki, Inoue Akira, Yano Seiji
Abstract excerpt
The BIM deletion polymorphism is reported to be associated with poor outcomes of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) treated with EGFR-TKIs, including gefitinib. We have shown that a histone deacetylase inhibitor, vorinostat, can epigenetically restore BIM function and apoptosis sensitivity to EGFR-TKIs in EGFR-mutant NSCLC cells with BIM deletion polymorphisms. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.